By Editor , 30 September 2026
LumiBot Debuts Dexterous Hands, Tactile Sensors at IROS 2026

Pittsburgh – September 30, 2026 -- LumiBot, a robotics startup founded just over a year ago and known in China as Shiyue Technology, unveiled a full stack of finger-shaped visuo-tactile sensors, dexterous hand hardware and manipulation foundation models at IROS 2026, where it was also selected to present at the conference's official Startup Session.

By Editor , 30 September 2026
Niutech Completes Restructuring, Signs RMB 198M UK Plastics Recycling Deal

Jinan – – September 30, 2026 -- Niutech Technology Group Co., Ltd. (SSE STAR Market: 688309) completed a group restructuring on August 26, 2026, consolidating nearly 40 years of industrial continuous pyrolysis operations as tightening EU recycling rules drive new orders for its waste tire and plastics processing lines.

By Editor , 30 September 2026

Hong Kong – September 30, 2026 -- City University of Hong Kong (CityUHK) climbed three places to rank 70th globally in the Times Higher Education (THE) World University Rankings 2027, its best result to date.

By Editor , 29 September 2026
iHuman Swings to Net Loss as MAUs Drop 14% Amid China Demographic Slump

Beijing – – September 29, 2026 -- iHuman Inc. (NYSE: IH) reported a second-quarter net loss of RMB17.5 million (US$2.6 million), reversing a net income of RMB30.7 million in the same period last year, as revenues fell 17.8% to RMB173.4 million (US$25.6 million) from RMB210.9 million.

By Editor , 29 September 2026
Envision Energy Named to Fortune's 2026 Change the World List

Shanghai – September 29, 2026 -- Envision Energy has secured a spot on Fortune's 2026 Change the World list for the third time, recognized for its Mission Gobi initiative pairing AI computing infrastructure with renewable energy in desert regions.

By Editor , 29 September 2026

San Francisco – September 29, 2026 -- Innovent Biologics reported an 84.6% overall response rate for its trispecific antibody IBI3003 at the recommended Phase 2 dose in heavily pretreated multiple myeloma patients, data presented in an oral session at the 23rd International Myeloma Society Annual Meeting 2026.

By Editor , 29 September 2026
Hengrui Licenses Oral GLP-1/GIP Drug to Novo in $2.6B Deal

Shanghai – – September 29, 2026 -- Hengrui Pharma has licensed its investigational obesity and diabetes drug HRS-1596 to Novo Nordisk in a deal worth up to 2.6 billion US dollars, including a 300 million dollar upfront payment.